A detailed exploration of Contingent Value Rights (CVRs), encompassing their definition, types, associated risks, and practical examples to illustrate their use in corporate finance and mergers & acquisitions.
Contingent Value Rights (CVRs) are legal agreements provided to shareholders of a company being acquired. These rights ensure the shareholders receive additional benefits if specific conditions or trigger events occur post-acquisition. The main purpose of CVRs is to bridge valuation gaps during mergers and acquisitions (M&A) and provide a form of financial security to the shareholders of the target company.
Earnout CVRs are conditional rights tied to the future performance of the acquired company. If the company meets pre-specified performance metrics (e.g., revenue targets or profit milestones), the shareholders receive a financial payout.
Milestone CVRs are triggered by specific events or achievements, such as the approval of a new product by regulatory authorities or the success of a particular project. These are common in acquisitions within highly regulated or research-driven industries, such as pharmaceuticals and biotechnology.
Price-based CVRs are linked to the market price performance of the acquirer’s stock or the combined entity. Shareholders may receive additional compensation if the stock price reaches certain levels within a predefined period.
The primary risk associated with CVRs is that the triggering event or performance metric may not be achieved, resulting in the CVRs becoming worthless. This is particularly significant in volatile or highly speculative industries.
CVRs often involve complex valuation mechanisms, and disputes may arise over whether the conditions have been met. The valuation of CVRs could be subjective and open to interpretation, leading to potential litigation or arbitration.
A prominent example of CVRs in action was seen in the acquisition of Genzyme by Sanofi in 2011. Sanofi issued CVRs to Genzyme shareholders, promising additional payments contingent on the performance of certain drugs in development and regulatory approval milestones. This structure helped bridge the valuation differences and align the interests of both parties in the transaction.
CVRs are widely used in M&A deals to provide a mechanism for bridging valuation gaps and addressing uncertainties about future performance. They are particularly useful in scenarios where the target company’s future prospects are uncertain or heavily contingent on the success of specific projects.
By issuing CVRs, companies can offer additional protection to their shareholders, thereby enhancing shareholder value and ensuring smoother transaction approvals.
While both earnouts and CVRs are contingent payments based on future performance, earnouts typically involve direct payments tied explicitly to business performance metrics, whereas CVRs may encompass a broader range of potential triggers.
CVRs share some similarities with equity derivatives in that they both provide value to holders based on future contingencies. However, CVRs are more specific to M&A activities and are often tailored to particular corporate events.